BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:17 PM
Jan 06, 2010
 |  BC Extra  |  Politics & Policy

FDA to reevaluate ESAs in CKD

FDA plans to convene a public advisory committee meeting this year to reevaluate the use of erythropoiesis-stimulating agents (ESAs) to treat anemia in patients with chronic kidney disease. The decision follows a paper by FDA's Center for Drug Evaluation and...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >